AI assistant
BridgeBio Pharma, Inc. — Director's Dealing 2024
Aug 21, 2024
30604_dirs_2024-08-20_9464a040-ffb9-4c8c-94b9-1631b8380855.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2024-08-16
Reporting Person: Kumar Neil (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-08-16 | Common Stock | M | 55537 | — | Acquired | 4952980 | Direct |
| 2024-08-16 | Common Stock | F | 28148 | $24.40 | Disposed | 4924832 | Direct |
| 2024-08-19 | Common Stock | S | 16192 | $24.3879 | Disposed | 4897443 | Direct |
| 2024-08-19 | Common Stock | S | 11197 | $25.1288 | Disposed | 4897443 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-08-16 | Restricted Stock Units | $ | M | 2394 | Disposed | Common Stock (2394) | Direct | |
| 2024-08-16 | Restricted Stock Units | $ | M | 33544 | Disposed | Common Stock (33544) | Direct | |
| 2024-08-16 | Restricted Stock Units | $ | M | 19599 | Disposed | Common Stock (19599) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1012722 | Indirect |
| Common Stock | 995686 | Indirect |
Footnotes
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 55,537 shares of Common Stock underlying the Reporting Person's RSUs.
F3: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.
F4: Represents the weighted average sale price of the shares sold ranging from $23.91 to $24.90 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F5: Represents the weighted average sale price of the shares sold ranging from $24.91 to $25.17 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F6: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
F7: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2021. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
F8: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
F9: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.